Regulatory FDA renews criticism of trial sponsors over transparency PharmaphorumThe FDA has launched a drive to get clinical trial sponsors to disclose the results of studies - even if they are negative.RegulatoryRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The FDA has launched a drive to get clinical trial sponsors to disclose the results of studies – even if they are negative. RegulatoryRead full story Post navigation Previous: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 UpdateNext: FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
